William Banyai - Twist Bioscience GM Development
| TWST Stock | USD 51.14 1.62 3.27% |
Executive
Dr. William Banyai, Ph.D., age 64, has served as our Chief Operating Officer and as a member of our board of directors since February 2013. Prior to cofounding Twist Bioscience, from April 2006 to March 2013, Dr. Banyai was the Vice President of Hardware Engineering at Complete Genomics Inc., a life sciences company that developed and commercialized a platform for sequencing and analyzing human genomes. Dr. Banyai was also previously a director at Glimmerglass Networks, a supplier of SDN enabled Intelligent Optical Switching and Optical Network Management solutions since 2013.
| Age | 70 |
| Tenure | 12 years |
| Phone | 800 719 0671 |
| Web | https://www.twistbioscience.com |
William Banyai Latest Insider Activity
Tracking and analyzing the buying and selling activities of William Banyai against Twist Bioscience stock is an integral part of due diligence when investing in Twist Bioscience. William Banyai insider activity provides valuable insight into whether Twist Bioscience is net buyers or sellers over its current business cycle. Note, Twist Bioscience insiders must abide by specific rules, including filing SEC forms every time they buy or sell Twist Bioscience'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
William Banyai over six months ago Disposition of 549 shares by William Banyai of Twist Bioscience at 37.43 subject to Rule 16b-3 |
Twist Bioscience Management Efficiency
The company has return on total asset (ROA) of (0.1639) % which means that it has lost $0.1639 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3836) %, meaning that it created substantial loss on money invested by shareholders. Twist Bioscience's management efficiency ratios could be used to measure how well Twist Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Daniel Rush | Waters | N/A | |
| John Kohl | Agilent Technologies | N/A | |
| Jakob Wedel | Illumina | N/A | |
| Matthew MD | Castle Biosciences | N/A | |
| Christian Haudenschild | Personalis | N/A | |
| Jenny Zheng | Illumina | N/A | |
| William IV | Danaher | 56 | |
| Bas Verhoef | Illumina | N/A | |
| Tobin Juvenal | Castle Biosciences | 65 | |
| Jeffrey CFA | EXACT Sciences | 46 | |
| Terilyn Monroe | Guardant Health | 57 | |
| Sheetal Parmar | Natera Inc | N/A | |
| Scott Davies | Illumina | N/A | |
| Sallilyn Schwartz | Illumina | N/A | |
| Bernhard Spiess | Castle Biosciences | 65 | |
| Jennifer Higgins | Guardant Health | N/A | |
| Peter Aggersbjerg | Mettler Toledo International | 56 | |
| Stephen Murphy | Guardant Health | N/A | |
| Lucas Glass | IQVIA Holdings | N/A | |
| David Green | ICON PLC | N/A | |
| Robert Schueren | Natera Inc | 62 | |
Management Performance
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.16 |
Twist Bioscience Corp Leadership Team
Elected by the shareholders, the Twist Bioscience's board of directors comprises two types of representatives: Twist Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Twist. The board's role is to monitor Twist Bioscience's management team and ensure that shareholders' interests are well served. Twist Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Twist Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Emily Leproust, President CEO, Director | ||
| William Banyai, GM Development | ||
| Patrick Finn, Vice President of Sales and Marketing | ||
| Dennis JD, Chief VP | ||
| Kevin Yankton, VP Officer | ||
| Chet Gandhi, Chief Officer | ||
| Michael Fero, Chief Officer | ||
| Siyuan Chen, Chief Officer | ||
| Aaron Sato, Chief Officer | ||
| Dennis Cho, General VP | ||
| James Thorburn, Chief Officer | ||
| Erin Smith, Sr Policy | ||
| Adam Laponis, Chief Officer | ||
| Paula Green, Vice President of Human Resources | ||
| Angela Bitting, Chief Affairs | ||
| Robert Werner, VP Officer |
Twist Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Twist Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.75) % | ||||
| Operating Margin | (0.54) % | ||||
| Current Valuation | 2.76 B | ||||
| Shares Outstanding | 59.58 M | ||||
| Shares Owned By Insiders | 1.94 % | ||||
| Shares Owned By Institutions | 98.06 % | ||||
| Number Of Shares Shorted | 9.18 M | ||||
| Price To Book | 6.24 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Twist Stock Analysis
When running Twist Bioscience's price analysis, check to measure Twist Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Twist Bioscience is operating at the current time. Most of Twist Bioscience's value examination focuses on studying past and present price action to predict the probability of Twist Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Twist Bioscience's price. Additionally, you may evaluate how the addition of Twist Bioscience to your portfolios can decrease your overall portfolio volatility.